

**ADVANCED BLADDER, TESTES AND KIDNEY**

GU DISEASE ORIENTED GROUP MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

*ROOM: ROSSETTI*

APRIL 30<sup>TH</sup>, 2011 – 7:00 AM – 9:00 AM

CO-CHAIRS : S. NORTH, W. KASSOUF, J. KNOX, A. KAPOOR, C. KOLLMANNSBERGER & P. CHUNG

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- *To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (renal, bladder and testicular cancer) in Canada.*
  - *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.*
  - *To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.*
  - *To provide a learning environment supportive to new investigators.*
  - *To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.*
- 

<b>7:00 am</b>	<b>Welcome</b>	
	<b>Studies Closed</b>	
<b>7:05 am</b>	Sunitinib in refractory testis cancer	<b>C. Kollmannsberger</b>
	<b>Ongoing Studies Updates</b>	
<b>7:10 am</b>	SPRUCE	<b>T. Cheng</b>
<b>7:15 am</b>	Ongoing CUOG/NCIC trials	<b>J. Knox</b>
	<b>Study Proposals</b>	
<b>7:20 am</b>	New concepts for kidney trials development	<b>A. Kapoor</b>
<b>7:30 am</b>	Neoadjuvant muscle invasive TCC	
	▪ cis/gem/mTOR	<b>A. Joshua</b>
	▪ cis/gem/OGX427	<b>S. North</b>
	▪ neoadjuvant RT in locally advanced TCC	<b>L. Eapen</b>

*continued on next page ...*

- 8:10 am** First line metastatic  
▪ cis/gem/mTOR **B. Eigl**
- 8:20 am** Second line metastatic  
▪ phase II cabazitaxel **K. Sridhar**  
▪ phase III albumin-bound paclitaxel **Y. Ko**
- 8:40 am** TIGER Study: Standard versus high-dose chemotherapy in relapsed testicular cancer **C. Kollmannsberger**
- 8:50 am** Standard versus accelerated BEP as first-line therapy for intermediate and poor prognosis patients **C. Kollmannsberger**
- 9:00 am** **Meeting Adjourned**